0

Synthetic Biologics Sinks 14% On Phase 2 Trial Failure For Relapsing-Remitting Multiple Sclerosis

Shares of Synthetic Biologics (NASDAQ:SYN) fell by 14% yesterday after the company reported on update on the phase 2 clinical trial for its Trimesta drug, used to treat patients with Relapsing-Remitting Multiple Sclerosis — RRMS. In RRMS, patients suffer from… Continue Reading

0

Inovio Shares Up This Week On New Vaccine Trials Targeting Virus Outbreaks

On Thursday Jan 28, 2016 shares of Inovio (NASDAQ:INO) closed the day up 7.64% after the company announced that it would start to recruit for a MERS vaccine trial with Gene One Life Science. MERS stands for Middle Eastern Respiratory… Continue Reading

0

Inovio Receives Grant From U.S. Army To Develop Needle-Free Device

On Tuesday January 19, 2016 Inovio Pharmaceuticals (NASDAQ:INO) had announced that it had received a research grant from the U.S. Army. More specifically the company is receiving a $500,000 grant from the U.S. Army’s Small Business Innovation Research — SBIR —… Continue Reading

0

Arena Pharmaceuticals Announces Collaboration With Privately Held Boehringer Ingelheim

In after-hours trading On Tuesday January 12, 2016 Arena Pharmaceuticals (NASDAQ:ARNA) announced a collaboration with privately held pharmaceutical company Boehringer Ingelheim. Together both companies will perform joint research aimed at discovering G protein-coupled receptors, which belongs to a group of orphan… Continue Reading

0

Advaxis Shares Continue To Fall As Investors Are Not Impressed With The New Scientific Advisory Board

Shares of Advaxis (NASDAQ:ADXS) have really been hit hard lately, and many hoped that news of the new scientific advisory board would help give it a boost. Unfortunately, the market was not impressed with the new Scientific Advisory board created… Continue Reading

0

Kalobios Faces More Uncertainty After Shkreli Arrest

On Thursday December 17, 2015 Martin Shkreli, CEO of Turing Pharmaceuticals and Kalobios Pharmaceuticals (NASDAQ:KBIO), was arrested by the FBI for Securities Fraud Charges. These charges were in relation to an old biotech company he ran known as Retrophin Inc. (NASDAQ:RTRX). Martin… Continue Reading

0

Advaxis Has Further Downside Since Partial Clinical Hold Announcement

Advaxis (NASDAQ:ADXS) has been struggling lately to make traction even with some recent news on poster presentations for its cancer immunotherapy treatment. That is because of the problem the company has been having with the FDA to get the partial clinical… Continue Reading

0

Merck And Amgen Form Partnership For Combo Immunotherapy Cancer Trials

(BiotechPickList) – On Friday Merck (NYSE:MRK) and Amgen (NASDAQ:AMGN) stated that they are coming together as a partnership, to tackle against a cancer known as Non-Hodgkin’s Lymphoma — NHL. This NHL cancer, is a type of cancer that starts in the… Continue Reading

0

Biomarin Fails To Impress The FDA Panel With Its Drug Kyndrisa

(BiotechPickList) – On Wednesday November 25, 2015 the FDA panel met to decide on the fate of Biomarin (NASDAQ:BMRN) Duchenne Muscular Dystrophy drug known as Drisapersen, or Kyndrisa. When some research notes were released by the panel, they noted many… Continue Reading